R‐<scp>CHOP </scp><i>versus</i> dose‐adjusted R‐<scp>EPOCH</scp> in frontline management of primary mediastinal B‐cell lymphoma: a multi‐centre analysisNirav N. Shah, Jakub Svoboda, Lauren E. Strelec et al.|British Journal of Haematology|2017Cited by 101
Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma—a “real world” studyNarendranath Epperla, Timothy S. Fenske, Mehdi Hamadani et al.|Hematological Oncology|2017Cited by 68
Maintenance rituximab or observation after frontline treatment with bendamustine‐rituximab for follicular lymphomaBrian T. Hill, Brad S. Kahl, Loretta J. Nastoupil et al.|British Journal of Haematology|2018Cited by 51
Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapyDavid A. Bond, Jonathon B. Cohen, Jeffrey M. Switchenko et al.|Blood Advances|2021Cited by 41
Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous TransplantBrian T. Hill, Jonathon B. Cohen, Jeffrey M. Switchenko et al.|Blood|2019Cited by 17